115 related articles for article (PubMed ID: 21571620)
21. Reimbursement for cancer treatment: coverage of off-label drug indications.
American Society of Clinical Oncology
J Clin Oncol; 2006 Jul; 24(19):3206-8. PubMed ID: 16717290
[TBL] [Abstract][Full Text] [Related]
22. Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study.
Joerger M; Schaer-Thuer C; Koeberle D; Matter-Walstra K; Gibbons-Marsico J; Diem S; Thuerlimann B; Cerny T
Eur J Clin Pharmacol; 2014 Jun; 70(6):719-25. PubMed ID: 24609468
[TBL] [Abstract][Full Text] [Related]
23. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
24. Prevalence of off-label use of oral oncolytics at a community cancer center.
Kalis JA; Pence SJ; Mancini RS; Zuckerman DS; Ineck JR
J Oncol Pract; 2015 Mar; 11(2):e139-43. PubMed ID: 25604593
[TBL] [Abstract][Full Text] [Related]
25. Off-label drug use in oncology: a systematic review of literature.
Saiyed MM; Ong PS; Chew L
J Clin Pharm Ther; 2017 Jun; 42(3):251-258. PubMed ID: 28164359
[TBL] [Abstract][Full Text] [Related]
26. What drives diffusion of new cancer therapies?
Schmidt C
J Natl Cancer Inst; 2015 Jun; 107(6):djv162. PubMed ID: 26032609
[No Abstract] [Full Text] [Related]
27. Off-label use of anti-cancer drugs in India: to be or not to be!
Gota V; Patial P
J Cancer Res Ther; 2011; 7(1):35-9. PubMed ID: 21546740
[TBL] [Abstract][Full Text] [Related]
28. Using price-volume agreements to manage pharmaceutical leakage and off-label promotion.
Zhang H; Zaric GS
Eur J Health Econ; 2015 Sep; 16(7):747-61. PubMed ID: 25193525
[TBL] [Abstract][Full Text] [Related]
29. [Off-label therapy in rheumatology].
Krüger K; Sieper J
Z Rheumatol; 2012 Feb; 71(2):99-100. PubMed ID: 22370799
[No Abstract] [Full Text] [Related]
30. Value and payment for oncology in the United States.
Robinson JC
Ann Pharm Fr; 2013 Sep; 71(5):285-90. PubMed ID: 24075699
[TBL] [Abstract][Full Text] [Related]
31. Comprehensive analysis of clinical development and regulatory submission promotion schemes for oncologic drugs as the Japanese national projects.
Nagai S; Ozawa K
Invest New Drugs; 2016 Dec; 34(6):777-791. PubMed ID: 27538583
[TBL] [Abstract][Full Text] [Related]
32. The complexity of covering off-label use for a multitude of oncology regimens.
Mehr SR
Am J Manag Care; 2012 Dec; 18(5 Spec No.):SP242-7. PubMed ID: 23301714
[No Abstract] [Full Text] [Related]
33. Re: How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question.
Cohen J; Looney W
J Natl Cancer Inst; 2010 Aug; 102(15):1207; author reply 1207-10. PubMed ID: 20651322
[No Abstract] [Full Text] [Related]
34. Policymaker, please consider your needs carefully: does outcomes research in relapsed or refractory multiple myeloma reduce policymaker uncertainty regarding value for money of bortezomib?
Franken MG; Gaultney JG; Blommestein HM; Huijgens PC; Sonneveld P; Redekop WK; Uyl-de Groot CA
Value Health; 2014 Mar; 17(2):245-53. PubMed ID: 24636383
[TBL] [Abstract][Full Text] [Related]
35. In-label and off-label use of respiratory drugs in the Italian paediatric population.
Baiardi P; Ceci A; Felisi M; Cantarutti L; Girotto S; Sturkenboom M; Baraldi E
Acta Paediatr; 2010 Apr; 99(4):544-9. PubMed ID: 20105140
[TBL] [Abstract][Full Text] [Related]
36. [Anticancer drugs off label used of: what do the experts think about?].
Debrix I; André T; Becker A; Lotz JP; Gligorov J; Boukari Y; Milleron B; Pene F; Flahault A
Bull Cancer; 2004 Oct; 91(10):769-77. PubMed ID: 15556877
[TBL] [Abstract][Full Text] [Related]
37. The ESMO-Magnitude of Clinical Benefit Scale for novel oncology drugs: correspondence with three years of reimbursement decisions in Israel.
Hammerman A; Greenberg-Dotan S; Feldhamer I; Birnbaum Y; Cherny NI
Expert Rev Pharmacoecon Outcomes Res; 2018 Feb; 18(1):119-122. PubMed ID: 28617621
[TBL] [Abstract][Full Text] [Related]
38. Off-label use reimbursement.
Cohen J; Wilson A; Faden L
Food Drug Law J; 2009; 64(2):391-403. PubMed ID: 19999289
[TBL] [Abstract][Full Text] [Related]
39. [Off label drug use in adult patients treated by anticancer chemotherapy].
Levêque D; Michallat AC; Schaller C; Ranc M
Bull Cancer; 2005 May; 92(5):498-500. PubMed ID: 15932813
[TBL] [Abstract][Full Text] [Related]
40. [Access to cancer care: the cost of treatment matters].
Tirelli U
Recenti Prog Med; 2014 May; 105(5):181-3. PubMed ID: 24873939
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
